Patients with associated morbidities are usually excluded from phase III trials on NHL therapy in the elderly, so that results obtained often cannot be reproduced in routine clinical practice. The CHOP, as well as CHOP-14 schedule with dose dense-intensification, cannot be administered to elderly patients with associated morbidities or severe reduction in liver and kidney functionality. In order to guarantee an adequate dose intensity of most active drugs to these patients, we formulated a modified bimonthly CHOP schedule, based on the reduction of single delivered dose of each drug and on shorter intervals between cycles (dose-dense intensification). We enrolled to treatment 10 patients (7 males and 3 females) aged between 71 and 82 years, affected by intermediate-high grade NHL, stage III and IV. Nine out of them were affected by two or more pathologic conditions; we found high IPI score in four patients. All patients completed the planned 12 courses of chemotherapy. We observed 7 complete responses, 2 partial responses and 1 progression of disease. Grade 2-3 neutropenia was observed in four patients and grade 2 anemia in two patients. We concluded that this modality of treatment might be useful in elderly and/or frail people affected by NHL; however a larger study should be performed.
|Translated title of the contribution||Age-tailored CHOP schedule (CEOPm) allows to maintain the dose intensity in aggressive non Hodgkin lymphomas of the elderly|
|Number of pages||7|
|Journal||Geriatric and Medical Intelligence|
|Publication status||Published - Jan 2006|
ASJC Scopus subject areas
- Geriatrics and Gerontology